AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00845689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: intravenous infusion of adenosine 0, 2 %
Study NCT00845689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine
Description: intravenous infusion of adenosine 0,2 %
Study NCT00845689 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Liver resection
Description: Liver resection with Pringle maneuver
Study NCT06699368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The ultra-high-power ablation group
Description: The ultra-high-power ablation group will use the QDOT ablation catheter with a power of 90W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g. The cold saline flow rate during ablation is 8ml/min, and the ablation device will adjust power and saline flow rate based on the electrode temperature at the tip of the QDOT ablation catheter. The target temperature is 60°C, and the cut-off temperature is 65°C, with an ablation endpoint of 4 seconds.
Study NCT06699368 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The high-power ablation group
Description: The high-power ablation group will use the STSF ablation catheter with a power of 50W, ablation points at site 3, inter-point distance maintained at 4-5mm, pressure maintained at 5-30g, and a cold saline flow rate of 15ml/min during ablation. The ablation endpoint for the posterior wall of the left atrium is an Ablation Index (AI) value of 360-410, for the anterior wall 450-480, and for the bottom and top of the left atrium 420-450.
Study NCT00845689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: Liver resection with Pringle maneuver
Study NCT05035550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Deceptive Placebo
Description: The placebos were ordered through Amazon from Zeebo® (Zeebo, Zeebo Effect, LLC, South Burlington, Vermont, USA). The placebos in this study were blue and white capsules containing Microcrystalline cellulose (an inert fiber). Ingredients include ones that are typically used to make pills including silica, gelatin, titanium dioxide, red #3 food coloring, and blue #1 food coloring. Placebo capsules were free of any active ingredients. These bottles were not branded specifically for the experiment, including the brand name (Zeebo Relief), description of the contents, directions, and a disclaimer. The investigators chose to not include a custom label for transparency and in order to increase non-deceptive placebo effects. Participants were instructed to take two pills a day, one in the morning and one in the evening.
Study NCT05741320 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: 27 questions will be asked to public to find out what is the role of anesthetists after the covıd pandemic
Study NCT06698510 — intervention group
Intervention type: DRUG
Intervention: Arpraziquantel 150mg dispersible tablet
Description: Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.
Study NCT06700278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Acupoint massage was performed three times daily, with each acupoint massaged for three minutes at an optimal pressure level that induced sensations of soreness, numbness, distension, or mild pain. This was conducted five days a week for three weeks, in addition to regular rehabilitation therapy provided five days per week.
Study NCT04740775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiBand Exceed
Description: Cyanoacrylate glue for closure of surgical wounds
Study NCT04740775 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiBand Rapid
Description: Cyanoacrylate glue for closure of surgical wounds
Study NCT05104697 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation
Description: All teens will receive active TMS; they will be randomly assigned to receive active TMS at either visit 1 or visit 2 (order counterbalanced)
Study NCT06439485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Given by PO
Study NCT06439485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by PO and IV
Study NCT06439485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by PO and IV
Study NCT06112431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator Intervention
Description: Participants randomized to the Patient Navigator Intervention Arm who require referral to ophthalmology will be teamed up with a Patient Navigator who will provide support with scheduling an in-office eye exams at either Columbia University Harkness Eye Institute, Harlem Hospital, or their own eye care provider. Each referred participant will receive several calls from a Patient Navigator over 2 years to discuss their understanding of their new ocular diagnosis and encourage adherence to in-office eye exam appointments.
Study NCT05112601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and/or blood samples
Study NCT05112601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and/or blood samples
Study NCT05112601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05112601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05112601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT05112601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05112601 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05112601 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05112601 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT05205044 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Apelin-13, Apelin-36
Description: Serum levels of Apelin-13 and Apelin-36
Study NCT04912050 — intervention group
Intervention type: DEVICE
Intervention: Tablo Hemodialysis System
Description: Renal Replacement Therapy between 12\< to ≤ 24 hours.
Study NCT06432920 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ResWave
Description: Prototype wearable in-phase chest wall vibration device
Study NCT06432920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResWave
Description: Prototype wearable in-phase chest wall vibration device
Study NCT04691453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QM-C Hysterectomy
Description: This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.
Study NCT04691453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: QM-B Hysterectomy
Description: Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.
Study NCT05225766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: used for peripheral block
Study NCT05163600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blod flow restriction training
Description: includes one strength and one endurance training
Study NCT05181683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casirivimab+Imdevimab
Description: Randomized 1:1 for intravenous (IV) or subcutaneous (SC) administration
Study NCT05881746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anatomical liver resection
Description: Based upon the segmental anatomy of the liver according to Couinaud system, anatomical resection (AR) was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
Study NCT05444192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM insoles
Description: computer-aided-design computer-aided-manufacture (CAD/CAM) insoles
Study NCT05881746 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nonanatomical liver resection
Description: Nonanatomical resection(NAR), known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.
Study NCT04951986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampicin up to 35 mg/kg/day for 14 days
Study NCT04951986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 750mg daily (for weight \<50kg) or 1 g daily (for weight >50 kg) daily for 14 days
Study NCT04951986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin, Pyrazinamide, Ethambutol and Isoniazid
Description: Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm
Study NCT05266339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-education training
Description: The strengthening exercises for rotator cuff muscles will be performed in the contralateral side of the affected side.
Study NCT04951986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin, Pyrazinamide, Ethambutol and Isoniazid
Description: Rifampicin 10 mg/kg; Isoniazid 5 mg/kg; Pyrazinamide 15 mg/kg; Ethambutol15 mg/kg in fixed dose combination administered per weight band. Standard of care control arm
Study NCT04951986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 1.5mg/kg/day for 14 days
Study NCT04951986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical to Prednisone
Study NCT05266339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard exercise program
Description: The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
Study NCT05266339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise program
Description: The standard exercise program, which prepared according to The American Society of Shoulder and Elbow Therapists' consensus statement on rehabilitation following arthroscopic rotator cuff repair, will be applied.
Study NCT05583136 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parietal tACS combined with visuo-attentional training
Description: Parietal tACS combined with visuo-attentional training
Study NCT05033353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of regional cerebral oxygenation
Description: Regional cerebral oxygenation was monitored using near-infrared spectroscopy (O3TM, Masimo, Irvine, CA) placed on the patient's forehead.
Study NCT05583136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham (placebo) tACS combined with visuo-attentional training
Description: Sham (placebo) tACS combined with visuo-attentional training
Study NCT05933395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant will be administered intramuscularly into the buttocks in combination with one of the other interventions as outlined above.
Study NCT05933395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Study NCT05933395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib will be administered orally in tablet form once daily with food in combination with fulvestrant administration as outlined above.
Study NCT05030493 — intervention group
Intervention type: DRUG
Intervention: mFOLFOX6 + panitumumab combination therapy
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study NCT05030493 — intervention group
Intervention type: DRUG
Intervention: mFOLFOX6 + bevacizumab combination therapy
Description: oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
Study NCT05237466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RECLAIM: Reducing Clutter and Increasing Meaning
Description: Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Each treatment session will involve a combination of motivational interviewing (MI) and sorting practice. The rationale behind the sorting practice is to develop the skill of sorting and the formation of a daily sorting routine. The MI portion of the initial session will involve an evaluation of client strengths and individual biopsychosocial goals. The initial and subsequent sessions will include a variety of MI techniques, including decisional balancing, developing discrepancy, personalized feedback, and reinforcement of responsibility of sense of self-efficacy.
Study NCT05237466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sorting Practice
Description: Participants will receive 16 weekly 1-hour treatment sessions in their home delivered by Masters-level clinicians with the assistance of undergraduate researchers. Clinicians will encourage participants to sort objects during each session while refraining from use of any specific cognitive or motivational therapeutic techniques. Participants will be asked to record the frequency and duration of any sorting/ discarding they did during the previous week.
Study NCT06522061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stream™ Platform
Description: Stream™ Platform consists of 5 main components: Origin™, Delta™ Monitor, Stream™ Application, Accessory Calibration Syringe(s), and Stream™ Cart. Origin™ is an inline biosensor system that can be attached between an off-the-shelf drainage catheter and evacuator bag/bulb system and is designed to monitor real-time changes in drained effluent characteristics (specifically pH and electrical conductivity (EC)) for the early identification of postoperative complications. Origin™ requires daily calibration (via Accessory Calibration Syringe(s)) for optimal performance and accuracy of its sensors. The Stream Application is a mobile application for displaying and analyzing data collected continuously via Origin™. Stream™ Application is pre-installed on Android mobile devices (called Delta™ Monitor) that are supplied by FluidAI. Origin connects to Stream Application via Bluetooth. Mobile carts/mounts, denoted Stream™ Carts/Delta Mounts, will be used to house the Delta™ Monitor.
Study NCT03569553 — intervention group
Intervention type: DRUG
Intervention: AIGIV
Description: Anthrax Immune Globulin Intravenous (Human)
Study NCT05458518 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean wound dressing removal
Description: The cesarean wound dressing is to be removed and the surgical wound exposed
Study NCT05583136 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham (placebo) tACS combined with phonics training
Description: Sham (placebo) tACS combined with phonics training
Study NCT06462118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astegolimab
Description: Participants will receive one SC dose of astegolimab in the abdomen, upper arm, or thigh.
Study NCT05458518 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cesarean wound dressing removal
Description: The cesarean wound dressing is to be removed and the surgical wound exposed
Study NCT05363891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natrunix
Description: Natrunix is a unique kind of drug-an immunoglobulin cloned from a naturally occurring immune response from a healthy human donor. Natrunix blocks inflammation in a unique way-it is the only therapeutic that exclusively neutralizes interleukin-1α (IL-1α), a crucial mediator of interleukin-1 inflammation. Targeting IL-1α directly using a natural human monoclonal antibody may provide a safer and more effective means of blocking interleukin-1 in rheumatoid arthritis.
Study NCT05363891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04299945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: concentrated beetroot juice (400mg of nitrate per serving)
Description: Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.
Study NCT04299945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: concentrated beetroot juice (trace amounts of nitrate per serving)
Description: Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.
Study NCT06444607 — intervention group
Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Blood draw in the context of routine patient care, when a venipuncture is already scheduled.
Study NCT06444607 — intervention group
Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Volunteering for blood draw.
Study NCT05265689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bike Club
Description: Administration of a bicycle safety education program to children ages 9-12 based on Let's Go NC!. Let's Go NC! includes observational skill checklists for instructors to track participant progress throughout the program, on-bicycle skills practice, hazard anticipation and avoidance, and traffic law importance and consequences. Additionally, participants will go on a capstone ride to practice their skills across varying transportation and recreation infrastructure and settings. The program will be administered at various sites across Iowa City.
Study NCT05265689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bike Club Plus
Description: Same as Bike Club, with the addition of a parent training component. Parents from these dyads will receive a training session on bicycling safety best practices, tips for practicing with their children at home, and feedback on how their child performed in the program (including areas in need of improvement).
Study NCT06323941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor Imagery plus therapeutic exercise
Description: Isometric exercises (20 minutes) to which will be added a motor imagery intervention (imagining movements without actually doing them).
Study NCT06323941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercises
Description: Isometric exercises (20 minutes) to which will be added a placebo motor imagery intervention (imagining a blue sky).
Study NCT02720874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rheumatoid arthritis educational booklet
Description: Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
Study NCT02720874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis educational booklet
Description: Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
Study NCT02720874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rheumatologic care
Description: At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
Study NCT02720874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse education and monthly calls
Description: Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.